Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab + Bevacizumab + FOLFIRI in mCRC
NCT05330429Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of magrolimab in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Dose-limiting Toxicities at 28 days, Adverse Events up to 36 weeks and 2 more. Started Jul 2022; status: terminated.
02
Drugs
magrolimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05330429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330429.